ADIL Stock Catalyst: Adial Pharmaceuticals Advances to Second Cohort in AD04 Pharmacokinetics Study

Jul 22, 2024 · 3:59pm ET

Progression in the clinical trial for Alcohol Use Disorder treatment.

Max move

+175.2%

High of day $75.00

Sparker timei

3:59pm ET

ADIL · Jul 22, 2024

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Adial Pharmaceuticals, Inc. (ADIL) announced on July 23, 2024, that it has moved to the second cohort in the pharmacokinetics study of its drug AD04, which is being developed for the treatment of Alcohol Use Disorder.

The company is conducting this study to evaluate the drug's properties and effectiveness in managing the disorder. The progression to the second cohort indicates continued momentum in the clinical trial process.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ADIL sparks.

Download Sniper App →

Catch the next ADIL-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →